Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission
Kite Pharmaceuticals $KITE has lined up a fresh batch of positive efficacy data for its lead CAR-T for advanced cases of acute lymphoblastic leukemia at ASH. And then later Sunday evening the biotech added that it has launched its rolling submission for a first approval.
Investigators turned up at the big ASH meeting to say that the drug spurred a complete remission in 9 of 11 evaluable patients — 82% — enrolled in the ZUMA-3 and ZUMA-4 Phase I studies for ALL in a preliminary review.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters